Skip to main content

Table 3 Asthma pricing—biologics

From: The role of antifungals in the management of patients with severe asthma

Product Company Target Year of market licensing Price of 6 months treatment
USA (USD) UK (USD) France (USD)
Xolair (omalizumab) Roche/Novartis IgE 2003 21.2 K 17.4 k 20.5 K
Nucala (mepolizumab) GSK IL-5 2015 19.2 K 7.2 K 7.3 K
Cinqair/Cinqaero (reslizumab) Teva IL-5 2016 17.4 K 8.4 K n/a
Fasenra (benralizumab) AstraZeneca / Kyowa Hakko Kirin IL-5R 2017 19.2 K 16.6 K 14.4 K
Dupixent (dupilumab) Sanofi-Genzyme Regeneron IL-4
IL-13
2018 21.1 K 10.8 K 10.4 K
  1. n/a, not applicable
  2. Sources: RedBook Online, accessed Jan 2020 [94]; MIMS Online, accessed Jan 2020 [95]; Akuthota and Weller UpToDate, 2018 [96]
  3. Note: The US price is the wholesale acquisition cost (WAC), which is the manufacturer's list price for a product when sold to wholesalers. The WAC may not represent actual transaction prices and does not include discounts or rebates Assumptions: Exchange rate of £1:$1.30, €1:$1.20
  4. US Prescribing Information and European SPCs; RedBook Online, accessed Feb 2019 [94]; MIMS Online, accessed Feb 2019 [95]
  5. Xolair dose depends on body weight and pre-treatment IgE serum levels. The US price is the wholesale acquisition cost (WAC), which is the manufacturer’s list price for a product when sold to wholesalers. The WAC may not represent actual transaction prices and does not include discounts or rebates Assumptions: (1) average body weight of 75 kg; (2) no sharing of vials between patients; (3) exchange rate of £1:$1.29, XE, com, Feb 2019